nigeria
current
struggl
sever
reoccurr
lassa
fever
lf
confirm
case
half
countri
state
world
health
organ
current
report
thousand
suspect
case
confirm
case
death
probabl
case
fatal
rate
addit
health
care
worker
infect
case
fatal
rate
lasv
first
discov
two
missionari
nurs
die
nigeria
lassa
viru
lasv
caus
agent
lf
belong
famili
arenavirida
endem
west
africa
figur
transmit
multimamm
rat
mastomi
natalensi
envelop
negativesens
rna
genom
genom
ambisens
consist
two
segment
small
segment
larg
l
segment
segment
encod
glycoprotein
precursor
gpc
express
envelop
viru
trimer
state
segment
also
encod
nucleoprotein
np
opposit
direct
encapsul
viral
genom
l
segment
encod
viral
matrix
protein
z
viral
rnadepend
rna
polymeras
l
transmit
human
lasv
present
case
mild
nondescript
diseas
howev
infect
result
sever
hemorrhag
fever
multiorgan
failur
incub
period
lf
typic
week
accompani
headach
fever
musclejoint
pain
diarrhea
vomit
elev
liver
enzym
ast
alt
hematocrit
sign
pathogenesi
vari
depend
anim
model
use
variou
vaccin
studi
howev
gold
standard
best
recapitul
human
condit
nonhuman
primat
nhp
figur
poor
prognosi
also
indic
accompani
edema
face
neck
abdomin
retrostern
pain
enlarg
lymph
node
andor
hemorrhag
conjunctiva
mucos
surfac
estim
infect
annual
basi
west
africa
make
lasv
primari
caus
hemorrhag
fever
worldwid
current
approv
vaccin
therapeut
treatment
prevent
lasv
question
except
offlabel
use
ribavirin
addit
histor
import
case
lasv
infect
humantohuman
transmiss
warrant
strong
develop
vaccin
treatment
modal
recent
bill
melinda
gate
foundat
along
collabor
partner
found
coalit
epidem
prepared
innov
cepi
sole
purpos
advanc
three
prioriti
pathogen
promis
preclin
candid
phase
iii
clinic
trial
event
futur
outbreak
cepi
along
initi
name
lasv
middl
east
respiratori
syndrom
coronaviru
nipah
viru
top
pathogen
prioriti
first
round
applic
despit
high
diseas
burden
lack
prevent
measur
lasv
signific
progress
made
identif
promis
preclin
candid
review
discuss
current
understand
lasv
immunobiolog
correl
protect
promis
vaccin
candid
prevent
lf
profession
antigenpres
cell
apc
macrophag
dendrit
cell
dc
primari
target
cell
lasv
infect
initi
infect
typic
involv
myeloid
lineag
cell
apc
earli
determin
diseas
progress
arenaviru
infect
activ
statu
viral
infect
apc
lasv
infect
apc
fail
undergo
activ
matur
lead
ineffect
antigen
process
present
despit
lasv
abl
replic
high
level
within
cell
contrast
mopeia
viru
mopv
nonpathogen
mammarenaviru
similar
lasv
one
induc
apc
activ
lead
effect
adapt
immun
also
replic
high
level
within
apc
infect
mopv
lead
classic
activ
apc
upregul
along
secret
innat
cytokin
type
interferon
ifn
immatur
state
infect
apc
persist
lasv
infect
even
though
cell
migrat
drain
lymph
node
infect
individu
earli
lasv
infect
type
ifn
respons
shown
import
mediat
protect
nhp
infect
lasv
strong
respons
within
first
day
infect
fare
better
anim
minim
earli
infect
addit
pathogen
lethal
lf
model
character
use
mice
lack
receptor
thu
unabl
respond
contrast
wildtyp
mice
resist
lasv
infect
type
ifn
signal
provid
import
barrier
viru
replic
well
bridg
virusspecif
adapt
immun
respons
therefor
abil
lasv
alter
type
ifn
respons
may
allow
uncheck
viral
replic
escap
protect
adapt
immun
respons
evid
lasv
antagon
innat
ifn
respons
cellular
mechan
lead
innat
adapt
immun
respons
may
critic
viral
clearanc
reduc
pathogenesi
alreadi
mention
lasv
prevent
apc
activ
matur
achiev
reduc
rna
sens
infect
dc
z
protein
lasv
also
bind
caspas
recruit
domain
rigi
prevent
signal
protein
nucleocapsid
protein
lasv
also
inhibit
type
ifn
signal
degrad
dsrna
bind
prevent
activ
also
evid
lasv
use
tam
receptor
axl
cell
entri
activ
receptor
lead
upregul
suppressor
cytokin
signal
protein
inhibit
type
ifn
signal
pathway
lasv
use
abovement
strategi
prevent
rigi
signal
lead
type
ifn
respons
infect
cell
strategi
play
import
role
prevent
apc
activ
lead
adapt
immun
respons
viral
clearanc
abil
alter
function
apc
like
critic
determin
pathogenesi
lasv
infect
absent
adapt
immun
respons
typic
seen
fatal
lf
case
overal
strong
evid
alter
apc
function
lasv
infect
correl
sever
diseas
outcom
knowledg
lasv
modul
innat
immun
system
import
implic
develop
vaccin
therapeut
vaccin
candid
target
glycoprotein
lasv
thu
express
protein
known
modul
innat
immun
candid
reassort
vaccin
express
lasv
nucleocapsid
protein
may
import
implic
immunogen
vaccin
candid
may
includ
protein
lasv
immunomodulatori
properti
activ
lasvspecif
cell
thought
play
import
role
infect
lf
develop
result
deplet
cell
nhp
model
cell
activ
earli
follow
lasv
infect
lasvnpspecif
memori
cell
detect
patient
year
follow
infect
activ
cell
lasv
infect
requir
apc
activ
matur
effici
antigen
process
present
infect
apc
infect
mopv
vitro
induc
much
stronger
tcell
respons
infect
lasv
indic
pathogen
lasv
infect
like
requir
suppress
innat
adapt
immun
respons
role
humor
respons
lasv
infect
less
clear
antibodi
respons
lasv
typic
weak
low
level
igm
igg
produc
earli
infect
antibodi
thought
mani
contribut
natur
recoveri
neutral
antibodi
produc
high
level
howev
role
antibodi
protect
lf
still
fulli
clear
mechan
antibodydepend
cellmedi
cytotox
complement
fixationactiv
opson
may
potenti
play
role
protect
diseas
sever
line
evid
point
strong
tcell
respons
lasv
critic
protect
lf
defect
tcell
respons
predomin
sever
lasv
infect
strong
tcell
respons
typic
seen
individu
control
infect
nhp
model
undetect
tcell
respons
correl
lethal
model
see
decreas
prolifer
activ
cytokin
product
well
lack
tcell
express
promot
diseas
progress
alreadi
discuss
lack
tcell
activ
like
due
inhibit
interact
infect
antigenprim
dc
present
lasv
peptid
cell
inde
lasvinfect
dc
unabl
activ
cell
vitro
dc
infect
mopv
readili
activ
cell
exact
mechan
tcell
deplet
clear
howev
abil
lasv
prevent
dc
activ
like
play
role
also
evid
lasvspecif
cell
contribut
diseas
macrophag
activ
result
deleteri
cellmedi
inflammatori
reaction
damag
secondari
lymphoid
organ
role
might
play
activ
suppress
tcell
respons
lasv
infect
unclear
suggest
like
import
protect
diseas
strong
tcell
respons
may
contribut
pathogenesi
examin
appropri
model
cell
activ
earli
lasv
infect
lasvspecif
cell
detect
follow
convalesc
despit
lack
lasvspecif
antibodi
strong
tcell
respons
np
gpc
lasv
seem
persist
year
follow
infect
indirect
evid
vaccin
studi
also
suggest
tcell
immun
import
protect
lf
strong
tcell
respons
induc
vacciniavector
lasv
vaccin
protect
lasv
challeng
addit
strong
activ
prolifer
cell
follow
lasv
challeng
seen
anim
surviv
infect
patient
recov
lf
lasvspecif
antibodi
level
present
soon
becom
undetect
lasvspecif
memori
cell
persist
also
evid
seroneg
survivor
lasv
suffer
lf
upon
reinfect
like
due
cellmedi
memori
respons
overal
specif
phenotyp
respond
cell
role
lasv
infect
remain
seen
strong
evid
suggest
effici
activ
prolifer
lasvspecif
cell
import
protect
lf
role
humor
immun
respons
lasv
infect
debat
cell
correl
surviv
difficult
determin
due
variabl
antibodi
respons
igm
igg
respons
occur
lasv
infect
lesser
degre
might
expect
play
major
role
protect
diseas
addit
neutral
antibodi
lasv
produc
larg
quantiti
infect
due
structur
properti
lasv
gpc
glycan
shield
potenti
limit
role
humor
respons
protect
despit
issu
import
antibodi
protect
lasv
may
underst
vesicular
stomat
viru
vaccin
express
lasv
glycoprotein
vsvlasvgpc
abl
induc
strong
humor
respons
lasv
gpc
provid
similar
protect
vaccin
induc
strong
tcell
respons
use
immun
plasma
convalesc
serum
treatment
lasv
infect
experiment
model
shown
mix
result
like
contribut
skeptic
protect
abil
antibodi
howev
use
human
monoclon
antibodi
guinea
pig
nhp
model
lf
shown
protect
monoclon
antibodi
use
protect
model
high
neutral
index
provid
evid
perhap
strong
neutral
respons
may
protect
lack
neutral
antibodi
produc
natur
infect
may
reason
correl
antibodi
product
surviv
observ
howev
anim
model
show
vaccinetherapeut
candid
abl
induc
high
neutral
titer
may
feasibl
protect
lasv
consider
progress
made
develop
preclin
vaccin
candid
prevent
lf
sinc
origin
descript
progress
made
sever
nonreplicationcompet
vaccin
includ
alphaviru
replicon
wholeinactiv
lasv
dna
electropor
addit
therapeut
develop
includ
preclin
test
ribavirin
favipiravir
current
best
therapeut
strategi
lasv
remain
favipiravir
administ
day
postinfect
guinea
pig
model
figur
treatment
human
monoclon
antibodi
test
guinea
pig
nhp
effect
administ
earli
diseas
cours
mind
best
candid
strong
efficaci
immunogen
lasv
prevent
base
replicationcompet
vaccin
modal
tabl
first
success
vaccin
direct
lasv
describ
recombin
vaccinia
viru
lister
strain
engin
express
np
lasv
given
outbr
hartley
guinea
pig
anim
receiv
recombin
viru
show
sign
diseas
viru
isol
blood
challeng
lasv
strain
nigerian
isol
control
anim
succumb
infect
day
interestingli
similar
dose
prototyp
strain
josiah
sierra
leon
isol
gener
lethal
hartley
guinea
pig
highlight
signific
divers
pathogen
heterogen
lf
second
studi
use
guinea
pigadapt
version
josiah
confirm
protect
efficaci
variou
recombin
strain
vaccinia
express
either
lasv
np
gpc
protect
respect
contrast
initi
vaccinia
experi
anim
includ
recombin
vaccin
vaccin
anim
show
sign
diseas
mild
fever
acut
viremia
less
control
anim
interestingli
combin
np
gpc
vaccinia
virus
led
poorer
outcom
protect
set
secondari
comprehens
studi
undertaken
rhesu
cynomolgu
macaqu
test
individu
vaccinia
vaccin
express
np
nineti
percent
anim
receiv
three
protein
surviv
lethal
lasv
challeng
consider
interest
anim
receiv
individu
protein
succumb
infect
np
surviv
stark
contrast
previou
guinea
pig
experi
despit
macaqu
gener
robust
antinp
antibodi
respons
addit
anim
receiv
combin
surviv
indic
protein
independ
integr
protect
lethal
diseas
initi
studi
combin
failur
wholeinactiv
lasv
protect
lethal
infect
indic
gpcspecif
cellmedi
compon
lasv
protect
take
advantag
close
relat
arenavirus
anoth
recent
vaccin
candid
design
use
gene
reassort
biseg
rna
genom
reassort
viru
subsequ
gener
ration
combin
nonpathogen
l
rna
mopv
rna
lasv
josiah
addit
sever
labadapt
mutat
led
attenu
strain
studi
strain
guinea
pig
vaccin
vaccin
complet
protect
lethal
lasv
infect
josiah
postvaccin
note
anim
undetect
viru
blood
tissu
found
convent
plaqu
assay
qrtpcr
indic
steril
immun
achiev
initi
studi
show
despit
signific
genom
heterogen
outbreak
strain
univers
vaccin
lasv
might
achiev
addit
vaccin
abl
provid
protect
given
day
lethal
challeng
vaccin
also
undergon
test
small
nhp
marmoset
particular
achiev
protect
accompani
steril
immun
howev
test
gold
standard
model
lasv
diseas
rhesu
cynomolgu
macaqu
warrant
also
substanti
safeti
concern
regard
genet
stabil
recombin
viru
well
safeti
hivinfect
individu
within
lasv
endem
region
anoth
recombin
vaccin
develop
research
group
make
use
yellow
fever
vaccin
one
safest
effect
vaccin
ever
develop
vaccin
highli
immunogen
induc
strong
cellmedi
immun
toler
recombin
addit
transgen
genom
initi
vaccin
develop
express
lasv
gpc
abl
protect
strain
guinea
pig
lethal
lasv
challeng
howev
genet
stabil
viru
less
ideal
gpc
express
wane
passag
attempt
remedi
genet
instabl
separ
recombin
virus
gener
express
well
attempt
shorten
transgen
mixtur
two
recombin
virus
protect
strain
guinea
pig
fatal
lasv
challeng
howev
steril
immun
achiev
unfortun
test
lasv
vaccin
marmoset
result
poor
immunogen
protect
lethal
lasv
challeng
safe
vaccin
develop
current
need
achiev
efficaci
vaccin
yellow
fever
lasv
despit
consider
list
preclin
candid
lasv
prevent
none
yet
shown
combin
efficaci
safeti
human
unpreced
ebola
outbreak
west
africa
result
document
case
infect
death
emerg
measur
sever
vaccin
acceler
phase
iii
clinic
trial
test
outbreak
one
success
vaccin
show
efficaci
ring
vaccin
trial
recombin
vesicular
stomat
viru
express
ebola
viru
gpc
vsvebovgpc
antibodi
implic
main
correl
protect
ebov
infect
respect
vsvebovgpc
vaccin
shown
long
last
month
nhp
model
howev
multipl
line
evid
suggest
main
correl
protect
lasv
involv
cellmedi
immun
despit
recent
studi
indic
monoclon
antibodi
therapi
suffici
protect
recombin
vsv
system
abl
toler
replac
vsv
glycoprotein
foreign
viru
glycoprotein
result
recombin
virus
attenu
safe
highli
immunogen
make
vaccin
strong
candid
lasv
prevent
first
descript
vsv
express
lasv
gpc
publish
shown
apathogen
mice
followup
studi
group
character
vsvlasvgpc
vaccin
nhp
cynomolgu
macaqu
vaccin
singl
dose
vsvlasvgpc
pfu
challeng
day
later
lethal
dose
josiah
vaccin
anim
surviv
challeng
overt
sign
diseas
chang
blood
chemistri
hematolog
consider
genet
variabl
strain
lasv
cluster
least
five
clade
clade
iiii
gener
local
nigeria
clade
iv
v
virus
isol
sierra
leonn
guinea
liberia
mali
renew
studi
almost
year
initi
character
vsvlasvgpc
vaccin
sought
test
whether
could
act
univers
vaccin
genet
distinct
lasv
isol
geograph
distinct
isol
shown
drastic
alter
diseas
manifest
thu
may
cover
vsvlasvgpc
vaccin
origin
construct
josiah
gpc
safronetz
et
al
discov
singl
josiahbas
vsv
vaccin
could
provid
protect
sever
isol
includ
sierra
leon
josiah
clade
iv
liberia
clade
iv
mali
sorombar
clade
v
nigeria
pinneo
clade
strain
guinea
pig
identifi
vsvlasvgpc
univers
vaccin
candid
addit
cynomolgu
macaqu
vaccin
vsvlasvgpc
show
overt
sign
diseas
challeng
liberian
isol
current
nigerian
outbreak
strain
lasv
thought
clade
iii
isol
yet
test
efficaci
vsvlasvgpc
vaccin
data
lend
strong
support
possibl
univers
lasv
vaccin
capabl
effect
lineag
region
potenti
widespread
use
vsvebov
wake
west
african
ebola
outbreak
import
aspect
consid
would
potenti
increas
preexist
immun
vsv
backbon
deploy
second
vsvbase
vaccin
region
mainli
vsvlasvgpc
may
provid
adequ
immunogen
protect
marzi
et
al
sought
address
concern
design
consecut
lasv
ebov
studi
cynomolgu
macaqu
initi
three
macaqu
vaccin
vsvlasvgpc
challeng
lethal
dose
lasv
josiah
three
anim
surviv
challeng
overt
sign
diseas
viru
detect
blood
addit
two
anim
show
sign
seroconvers
challeng
suggest
nearsteril
immun
singl
control
anim
infect
parallel
rapidli
succumb
classic
lasv
diseas
day
three
surviv
anim
vaccin
dose
vsvebovgpc
subsequ
challeng
lethal
dose
ebov
day
later
despit
signific
vsv
antibodi
titer
prior
vsvebovgpc
vaccin
immun
anim
surviv
challeng
singl
control
anim
succumb
ebov
diseas
day
importantli
studi
show
vsv
vector
potenti
use
repeatedli
protect
ebov
lasv
infect
africa
vsv
recombin
system
extrem
robust
potenti
express
toler
express
multipl
transgen
combin
ebov
lasv
glycoprotein
express
singl
vaccin
feasibl
signific
potenti
prevent
futur
outbreak
ebov
lasv
west
africa
unfortun
despit
best
effort
cepi
take
lead
prepar
futur
outbreak
current
resurg
lasv
nigeria
caught
intern
commun
ill
prepar
recombin
vsvlasvgpc
vaccin
among
one
lead
candid
develop
thu
far
target
acceler
develop
cepi
collabor
partner
sever
import
question
need
rapidli
address
face
new
outbreak
mainli
genet
makeup
viru
undergon
signific
chang
allow
spread
readili
becom
pathogen
also
import
character
new
nigerian
outbreak
strain
lasv
test
efficaci
preclin
vaccin
candid
particular
vsvlasvgpc
vaccin
lasv
viru
thrust
intern
spotlight
continu
neglect
emerg
pathogen
critic
import
howev
strong
clinic
candid
pois
test
phase
iii
trial
prevent
vaccin
could
soon
approv
use
region
author
report
conflict
interest
work
